Krsnaa Diagnostics Limited Q2 Revenue Rises 31.6% to ₹271 Crore

Krsnaa Diagnostics Limited reported consolidated revenue from operations of ₹270.97 crore for Q2 FY27, a 31.6% year-on-year increase, while profit attributable to equity holders rose 2.7% to ₹24.59 crore for the quarter ended September 30, 2026. The results show strong revenue expansion, although profit growth remained comparatively modest.

What did Krsnaa Diagnostics report for Q2 FY27?

Krsnaa Diagnostics reported revenue from operations of ₹270.97 crore in the September quarter of FY27, compared with ₹205.99 crore in Q2 FY26. The increase was driven by volume growth across the company's radiology and pathology segments, according to its results presentation.

Consolidated profit for the period was ₹25.82 crore, versus ₹23.95 crore a year earlier. Profit attributable to equity holders, the net-profit measure cited in the company's quarterly update, was ₹24.59 crore compared with ₹23.95 crore in Q2 FY26. Basic earnings per share, not annualised, stood at ₹7.64.

The board approved the unaudited standalone and consolidated financial results at its meeting on November 2, 2026. The company had previously informed exchanges that the board would consider the Q2 and half-year FY27 results on that date.

Why did revenue grow faster than profit?

Krsnaa Diagnostics said revenue growth reflected strong volumes in its radiology and pathology businesses. Its results presentation also showed retail revenue increasing 35% year on year. The company is pursuing growth through Rajasthan pathology operations and public-private partnership PET-CT initiatives, which extend its diagnostic network and service footprint.

However, the increase in revenue did not translate into a similar rise in profit attributable to equity holders. EBITDA margin eased to 27% in Q2 FY27, based on the company's presentation. Tax expense increased to ₹8.18 crore from ₹7.62 crore in the year-earlier quarter, a rise of 7.4%, which was one of the factors weighing on the pace of net-profit growth.

The reported figures therefore indicate a quarter in which operating scale expanded significantly, but margins and tax costs limited the growth in earnings attributable to shareholders. Revenue growth was more than eleven times the rate of growth in attributable profit.

What is the tax matter disclosed by Krsnaa Diagnostics?

Krsnaa Diagnostics disclosed tax demands of ₹62.69 crore that remain under appeal. The company also said it had deposited ₹10.28 crore under protest in connection with tax orders and is appealing those orders.

Management has stated that it expects no material impact from the tax assessments. The matter remains relevant because the company has made a deposit while pursuing its appeals, and the final outcome is not stated in the quarterly results. Investors will need to monitor subsequent disclosures for any development in the appeals or changes in the company's assessment of the financial impact.

The higher tax expense reported during Q2 also provides context for the difference between strong revenue growth and lower growth in profit. It does not, by itself, establish the eventual outcome of the pending tax matters.

How does the Q2 result compare with recent performance?

Krsnaa Diagnostics entered Q2 after reporting Q1 FY27 revenue of ₹243 crore, up 26% year on year, while Q1 net income was ₹16.55 crore. Q2 revenue of ₹270.97 crore was higher than the preceding quarter's reported revenue, and profit attributable to equity holders of ₹24.59 crore was also above the Q1 net-income figure.

For the first half of FY27, consolidated revenue reached ₹506.50 crore. The sequential improvement in the September quarter followed a first quarter in which the company reported lower profit margin, citing higher expenses, despite revenue growth.

For investors, the key comparison is between sustained demand-led revenue expansion and the company's ability to protect profitability as it expands. The Q2 result supplied evidence of continued top-line growth but also showed that earnings growth remained constrained relative to sales growth.

What does the result mean for investors and operations?

The Q2 numbers show that Krsnaa Diagnostics is adding revenue through its core diagnostics operations, including radiology, pathology and retail channels. Its total consolidated assets stood at ₹2,063.58 crore as of September 30, 2026, indicating the asset base supporting these operations.

The company has scheduled a post-earnings conference call for November 3, 2026, at 12:30 PM IST. That interaction may provide further detail on operating volumes, margin movement, retail growth, expansion projects and the tax appeals. No share-price movement or market reaction was stated in the supplied information.

Conclusion

Krsnaa Diagnostics delivered a 31.6% increase in Q2 FY27 revenue to ₹270.97 crore, supported by growth in radiology, pathology and retail activity. Profit attributable to equity holders increased 2.7% to ₹24.59 crore, showing that tax costs and margin pressure moderated the benefit of higher revenue.

The next disclosed event is the November 3 post-earnings conference call. Investors will watch for management's commentary on EBITDA margin, the progress of Rajasthan pathology and PPP PET-CT initiatives, and the status of tax demands of ₹62.69 crore that remain under appeal.